| Document |
Document Title |
|
WO/2001/068585A1 |
A compound represented by the general formula (I) and a salt thereof: R?1¿-A-X-NHCO-Y-R?2¿ wherein R?1¿ is an optionally substituted heterocyclic group or optionally substituted phenyl; R?2¿ is optionally substituted fused phenyl, op...
|
|
WO/2001/068611A1 |
Therapeutically active compounds of formula (I) in which R¿1? to R¿4? means hydrogen, alkyl, alkenyl, aryl, arylalkyl, carboxyalkyl, hydroxyalkyl or halogenalkyl, or R¿2? and R¿3? form a ring of 5-7 carbon atoms, R¿5? to R¿9? means...
|
|
WO/2001/064635A1 |
Anlogs of ningalin B lacking inherent cytotoxic activity may be employed to reverse multi-drug resistant (MDR) phenotype and to resensitize transformed cells, including a human colon cancer cell line (HCT116/VM46), with respect to a vari...
|
|
WO/2001/058901A1 |
A pyrrolopyridazine compound represented by the general formula (I) or a pharmacologically acceptable salt thereof. (In the formula, R?1¿ is C¿2-6? alkenyl, C¿2-6? halogenoalkenyl, optionally substituted C¿3-7? cycloalkyl, or optiona...
|
|
WO/2001/058853A1 |
Compunds of formula (1 and 1-1), wherein R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, A, B have the meanings given within.
|
|
WO/2001/056997A1 |
The invention provides a process for preparing piperazic acid derivatives of the general formula (I), wherein R?1¿ is C¿1-20?-alkyl and R?2¿ is hydrogen, C¿1-6?-alkyl, C¿1-6?-haloalkyl, C¿1-6?-alkoxy, allyloxy, 2,2,2-trichloroethox...
|
|
WO/2001/053274A1 |
Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to ...
|
|
WO/2001/046194A2 |
The invention provides a process for preparing a compound of formula (I) and pharmaceutically acceptable derivatives thereof in which: R?0¿ is halogen, C¿1-6?alkyl, C¿1-6?alkoxy, C¿1-6?alkoxy substituted by one or more fluorine atoms...
|
|
WO/2001/045703A1 |
The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, a...
|
|
WO/2001/046127A1 |
The invention specifically concerns pseudopeptides derived from functionalised amino acids, comprising fatty acid chains fixed in the form of amide on the amine functions of the pseudopeptide and whereof one of the ends bears a functiona...
|
|
WO/2001/046126A1 |
The invention relates in particular to pseudodipeptides which are derived from functionalised aminoacids and which comprise fatty acid chains that are fixed on the amine functions of the pseudodipeptides in amide form, one of the ends of...
|
|
WO/2001/036388A1 |
The present invention relates to N-substituted cyclic aza compounds, pharmaceutical compositions comprising such compounds, and methods of their use for effecting neuronal activities.
|
|
WO/2001/034603A2 |
Disclosed are compounds of formula (I) and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X¿1?, Y and Z are as defined herein. These compounds bind with high selectivity and/or high affinity to the benzodiazepine site o...
|
|
WO/2001/034151A1 |
Methods for the treatment of a proliferative disorder are provided in which a subject in need of such treatment is administered an effective amount of a compound selected from: compounds of formula (I) or a pharmaceutically acceptable sa...
|
|
WO/2001/032631A2 |
The invention provides compounds of formula (I), wherein R¿1?-R¿8? ang A-G have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions compr...
|
|
WO/2001/032604A1 |
Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the activation of soluble guanylate cyclase, wherein: R¿1? and R¿2? are the same or different and each repre...
|
|
WO/2001/030766A1 |
The compounds of formula (I) in which R1, R2, A, B and Ar have the meanings as given in the description are novel effective PDe4 inhibitors.
|
|
WO/2001/028560A1 |
Levosimendan, or (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phe
nyl]hydrazono]propanedinitrile, which has been previously suggested for the treatment of congestive heart failure is useful in the treatment of sick sinus synd...
|
|
WO/2001/025229A1 |
Amide compounds of formula (I) wherein R?1¿ is an N-containing heterocyclic group selected from imidazolyl, triazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, each of which may be substituted with one or more lower alkyl groups...
|
|
WO/2001/023375A2 |
Substituted pyridines and pyridazines having angiogenesis inhibiting activity and generalized structural formula (I) wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any ...
|
|
WO/2001/019822A1 |
This invention relates to a compound capable of binding to a picornavirus capsid comprising two or more capsid binding moieties.
|
|
WO/2001/017972A2 |
The invention relates to novel compounds of formula (I), wherein the substituents have the significance cited in claim (1) and the agronomically compatible salts, isomers and enantiomers of said compound, which are suitable for use as he...
|
|
WO/2001/016137A1 |
This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
|
|
WO/2001/010825A1 |
Novel bactericides having an excellent controlling effect on plant disease injury (in particular, wheat powdery mildew and cucumber gray mold) without exerting any undesirable effect on crops. Carbamate derivatives represented by general...
|
|
WO/2001/009105A1 |
4,6-dichloropyrimidine is advantageously produced from 4-chloro-6-methoxypyrimidine by using phosgene as chlorinating agent and working in the presence of nitrogen-containing auxiliary agents.
|
|
WO/2001/007416A1 |
The invention relates to a method of producing pyridazine carboxylic acid derivatives of the general formulae (Ia) or (Ib), wherein R?1¿ represents a group of the formula -OR?3¿ or -NR?4¿R?5¿, R?2¿ represents hydrogen, chlorine, a g...
|
|
WO/2001/007415A1 |
The invention relates to a method of producing pyridazine-3,6-dicarboxylic acid esters of the general formula (I), wherein R represents C¿1-10? alkyl, C¿3-8? cycloalkyl or aryl-C¿1-4?-alkyl, by reacting 3,6-dichloropyridazine with car...
|
|
WO/2001/004097A2 |
Cyclic delocalized cations joined together by spacer groups, with anions of equal number to cations to maintain charge neutrality, are disclosed. These spacer groups may be organic or inorganic in origin and may vary in length. The space...
|
|
WO/2001/004099A1 |
The invention relates to benzoyl derivatives of formula (I) and the physiologically acceptable salts and solvates thereof, wherein R?1¿, R?2¿, R?3¿, R?4¿, R?5¿ and R?6¿ have the meanings cited in Claim 1. Said derivatives inhibit p...
|
|
WO/2001/002359A1 |
Heterocyclic compounds represented by the following general formula which have inhibitory effects on AP-1 activity, NF-Kappa B activity, inflammatory cytokine production, matrix metalloprotease production, inflammatory cell adhesion fact...
|
|
WO/2001/000595A1 |
The invention relates to a novel method for the production of 2-heterocyclyl methyl benzoic acid derivatives of general formula (I), wherein n, X and Z have the meaning cited in the description, providing good yields and high purity. The...
|
|
WO/2001/000589A1 |
The invention relates to the area of erythropoiesis, in particular to substituted 6-carboxyphenyldihydropyridazinone derivatives of general formula (I), to methods for producing them and to their use as medicaments, preferably for preven...
|
|
WO/2001/000590A1 |
The invention relates to the area of erythropoiesis and in particular, to substituted 6-[4(oxymethyl)-phenyl]-dihydropyridazinones of general formula (I), to a method for producing them and to their use as medicaments, preferably for pre...
|
|
WO/2001/000575A1 |
Heterocyclic dicarboxylic acid diamide derivatives represented by general formula (I): wherein R?1¿, R?2¿ and R?3¿ represent each H, optionally halogenated C¿3-6? cycloalkyl, etc.; Het represents a 5- or 6-membered heterocycle; X and...
|
|
WO/2001/000581A1 |
The present invention includes array of new chiral ligands that are optically active or racemic. These ligands are bidentate, tridentate, tetradentate or pentadentate ligands which include P-P, P-N, N-N, mixed P-N, Schiff base or carbene...
|
|
WO/2000/078746A1 |
This invention relates to compounds of formula (I): Het-A-Alk-W-Ar-C(X?2¿)=NO-X?1¿, their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment...
|
|
WO/2000/072811A1 |
The present disclosure describes methods for treating hair loss in mammals, including arresting and/or reversing hair loss and promoting hair growth. The methods comprise administering a cardiac-sparing coumpound having a structure as de...
|
|
WO/2000/073276A2 |
The invention relates to carboxylic acid derivatives of formula (I), whereby the substituents have the meanings as explained in the description. The invention also relates to the production and use of said novel carboxylic acid derivativ...
|
|
WO/2000/068204A1 |
The invention relates to novel substituted benzoyl ketones of formula (I), wherein n represents 0, 1, 2 or 3; A represents a simple bond or alkanediyl (alkylene); R?1¿ represents hydrogen or optionally substituted alkyl or cycloalkyl; R...
|
|
WO/2000/067734A2 |
The invention relates to the use of phthalazine derivatives as inhibitors of the enzyme poly(ADP-ribose)polymerase or PARP (EC 2.4.2.30), and to their use as inhibitors of PARP-homologous enzymes. These phthalazine derivatives also exhib...
|
|
WO/2000/068190A2 |
Compounds of Formula (1) and Formula (2) where the symbols have the meaning defined in the specification, have retinoid, retinoid antagonist or retinoid negative hormone like biological activity.
|
|
WO/2000/068191A1 |
Compounds of Formula (1), Formula (2), Formula (3) and Formula (4) wherein the symbols have the meaning assigned to them in the disclosure have retinoid-like biological activity.
|
|
WO/2000/064430A1 |
Apoptosis inhibitors containing compounds represented by general formula (1) or pharmaceutically acceptable salts thereof: wherein Ar represents phenyl, an aromatic heterocycle, etc.; n is an integer of 0, 1 or 2; R represents hydrogen o...
|
|
WO/2000/063181A1 |
The invention relates to the use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins. The maduraphthalazine derivatives of formula (4) are capable of inhibiting the effect of the cytokines interleukin-2, interleuk...
|
|
WO/2000/059891A1 |
The invention relates to a method for producing 4-amino-5-chloro-1-phenyl pyridazinone-(6) by reacting 4,5-dichloro-1-phenyl pyridazinone-(6) with aqueous ammonia in the presence of a catalyst. According to the invention, a catalyst is u...
|
|
WO/2000/059890A1 |
The invention relates to tetrahydropyridazine derivatives selected from the following group: 1-(4-ureido-benzoyl) -3-(3-ethoxy- 4-methoxy-phenyl) -1,4,5,6-tetrahydro- pyridazine, 1-(4-nicotinoylamino- benzoyl)-3- (3-propoxy-4- methoxyphe...
|
|
WO/2000/059484A2 |
The invention relates to the use of compounds of formula (I), wherein R?1¿, R?2¿, Q and B have the meanings given in claim 1, and/or their physiologically compatible salts for producing a medicament for treating osteoporosis, tumours, ...
|
|
WO/2000/058293A2 |
The present invention relates to compounds of formula (I) wherein R?1¿, R?2¿, R?3¿ and R?4¿ are as defined in claim 1 and pharmaceutically acceptable salts thereof. The compounds are glucokinase activators which increase insulin secr...
|
|
WO/2000/058306A1 |
The invention relates to novel substituted benzoylpyrazoles of the general formula (I), in which Z is a possibly substituted 4 to 12-membered, saturated or unsaturated, monocyclic or bicyclic heterocyclic grouping which contains between ...
|
|
WO/2000/050408A1 |
Pyridazin-3-one derivatives of general formula (1) or salts of the same, exhibiting an excellent interleukin-1$g(b) production inhibiting effect; and medicines containing the derivatives or the salts as the active ingredient wherein Ar?1...
|
